Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...

The colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $89.88 which represents a slight increase of $0.74 or 0.83% from the prior close of $89.14. The stock opened at $90.19 and ...

Velia Therapeutics has announced it is winding down its operations while staying loyal to the therapeutic potential of ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) yesterday and set a ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) on January 7 and set a price ...

the Royalty Agreement, under which Galapagos will gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to Gilead on net sales of ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed ... head of Merck Research Laboratories. "Novel HIV treatment options that allow for less frequent ...

Stephen King has a slew of new books coming out in the next few years, but long-teased sequel he finally confirmed is the ...

Aardvark Therapeutics, Inc. (Aardvark), a clinical-stage biopharmaceutical company focused on developing novel, ...